| Name | Title | Contact Details |
|---|---|---|
E. Atkinson |
Executive Vice President and Chief Technical Operations Officer | Profile |
Michael Kennedy |
Director, Cyber Security | Profile |
Michael Daly |
Vice President & Chief Information Security Officer | Profile |
Tom Philbin |
Senior Director, Head of Enterprise Architecture | Profile |
Stephen Schoepke |
Associate Director, Information Security/Sr. Privacy Engineer | Profile |
Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.
Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients. Neon Therapeutics is a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes. We pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies. Our platform seeks to identify and harness the most therapeutically relevant neoantigens present within each patient`s tumor, and comprises three key elements that form an iterative feedback loop: our RECONTMBioinformatics Engine; our deep capabilities in peptide chemistry and manufacturing; and our combined NEON-STIMTM T cell biology and immune-monitoring expertise. Our company builds on more than a decade of pioneering work by our world-class scientific founders across multiple leading global institutions including the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, MD Anderson Cancer Center, the Netherlands Cancer Institute and Washington University in St. Louis. Our founders were central to the development of both the fields of immuno-oncology and neoantigens and have published a number of seminal papers outlining the importance of neoantigens as critical immune targets for treating cancer.
High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.
Complete Testing Solutions is a Gilbert, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GeneSage is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.